Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue SUPPL. 1, 2005, Pages

  Glasmacher, Axel ^a   Prentice, Archibald Grant ^b  

^a UNIVERSITY OF BONN   (Germany)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Acute leukaemia; Fluconazole; Invasive fungal infections; Itraconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ASTEMIZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIGOXIN; FLUCONAZOLE; ITRACONAZOLE; MICONAZOLE; MIDAZOLAM; NIFEDIPINE; PLACEBO; QUINIDINE; TACROLIMUS; TAXANE DERIVATIVE; TERFENADINE; VERAPAMIL; VINCA ALKALOID; WARFARIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ASPERGILLOSIS; ASPERGILLUS; BONE MARROW TRANSPLANTATION; CANDIDA; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART DISEASE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; HYPOKALEMIA; INFECTION CONTROL; KIDNEY DISEASE; LIVER DISEASE; META ANALYSIS; MORTALITY; MYCOSIS; NAUSEA; NEUTROPENIA; PATIENT SELECTION; PROPHYLAXIS; REVIEW; SYSTEMATIC REVIEW;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; FLUCONAZOLE; HEMATOLOGIC NEOPLASMS; HUMANS; ITRACONAZOLE; MYCOSES; NEUTROPENIA; STEM CELL TRANSPLANTATION;

EID: 24144448601     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki221     Document Type: Review

References (72)

1. Glasmacher A, Prentice AG, Gorschluter M et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for haematological malignancies: Evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21: 4616-26.
2. Groll A, Shah PM, Mentzel C et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23-32.
3. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000; 110: 273-84.
4. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32 358-66.
5. Bennett JE, Powers J, Walsh T et al. Forum report: Issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2003; 36: S117-S122.
6. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
7. Ruhnke M, Bohme A, Buchheidt D et al. Diagnosis of invasive fungal infections in hematology and oncology. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 Suppl. 2: S141-8.
8. Bodey GP, Bueltmann B, Duguid W et al. Fungal infections in cancer patients: An international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11: 99-109.
9. Donnelly JP. Symptoms and diagnosis of nosocomial fungal infections - state-of-the-art. Eur J Med Res 2002; 7: 192-9.
10. Erjavec Z, Verweij PE. Recent progress in the diagnosis of fungal infections in the immunocompromised host. Drug Resist Update 2002; 5: 3-10.
11. Caillot D, Cassanovas O, Bernard A et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139-47.
12. Trifilio S, Verma A, Mehta J. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: Heterogeneity of current clinical practice. Bone Marrow Transplant 2004; 33: 735-9.
13. Lass-Flörl C, Salzer GM, Schmid T et al. Pulmonary Aspergillus colonization in humans and its impact on management of critically ill patients. Br J Haematol 1999; 104: 745-7.
14. Gotzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 1997; 314: 1238-44.
15. Gotzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database Syst Rev 2002; CD000026.
16. Bow EJ, Laverdiere M, Lussier N et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: A meta analysis of randomized-controlled clinical trials. Cancer 2002; 94: 3230-46.
17. Kanda Y, Yamamoto R, Chizuka A et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89: 1611-25.
18. Petticrew M. Systematic reviews from astronomy to zoology: Myths and misconceptions. BMJ 2001; 322: 98-101.
19. Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003; 101: 3365-72.
20. Gotzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database Syst Rev 2000; CD002033.
21. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 1989; 86: 668-72.
22. Goldstone AH, O'Driscoll A. Early AmBisome in febrile neutropenia in patients with haematological disorders. Bone Marrow Transplant 1994; 14: 15-7.
23. Pizzo PA, Robichaud KJ, Gill FA et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101-11.
24. Egger M, Smith GD, O'Rourke K. Rationale, potentials and promise of systematic reviews. In: Egger M, Smith GD, Altman DG, eds. Systematic Reviews in Health Care: Meta-analysis in Context. London, UK: BMJ Publishing Group, 2001; 3-19.
25. Egger M, Smith GD, Phillips AN. Meta-analysis: Principles and procedures. BMJ 1997; 315: 1533-7.
26. Antman EM, Lau J, Kupelnick B et al. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA 1992; 268: 240-8.
27. Egger M, Smith GD. Meta-analysis. Potentials and promise. BMJ 1997; 315: 1371-4.
28. van Burik J-A, Ratanatharathorn V, Lipton J et al. Randomized, double-blind trial of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. In: Programs and Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA, 2002. Abstract M-1238, p. 401. American Society for Microbiology, Washington, DC, USA.
29. Mattiuzzi GN, Kantarjian H, Alvarado CJ et al. Intravenous itraconazole vs caspofungin prophylaxis in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. In: Programs and Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract M-984, p. 451. American Society for Microbiology, Washington, DC, USA.
30. Marr KA, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-61.
31. Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 705-13.
32. Marr KA, Crippa F, Leisenring W et al. Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic HSCT recipients: results of a randomized trial. Blood 2002; 100 Suppl, Part 1: 215a (Abstract).
33. Glasmacher A, Hahn C, Molitor E et al. Itraconazole through levels in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-cyclodextrin oral solution or coated-pellet capsules. Mycoses 1999; 42: 591-600.
34. Prentice AG, Warnock DW, Johnson SA et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J Antimicrob Chemother 1995; 36: 657-63.
35. Prentice AG, Warnock DW, Johnson SA et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother 1994; 34 247-52.
36. Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-33.
37. Marr KA, Leisenring W, Crippa F et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103: 1557-9.
38. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998; 42: 3018-21.
39. Berenguer J, Ali NM, Allende CM et al. Itraconazole for experimental pulmonary aspergillosis: Comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother 1994; 38: 1303-8.
40. Glasmacher A, Hahn C, Molitor E et al. Minimal effective through concentrations for antifungal prophylaxis with itraconazole: A case-control study. In: Programs and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA, 2002. Abstract M-890, p. 393. American Society for Microbiology, Washington, DC, USA.
41. Glasmacher A, Hahn C, Leutner C et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42: 443-51.
42. Louie A, Liu QF, Drusano GL et al. Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans. Antimicrob Agents Chemother 1998; 42: 1512-4.
43. Louie A, Drusano GL, Banerjee P et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998; 42: 1105-9.
44. Castagnola E, Machetti M, Bucci B et al. Antifungal prophylaxis with azole derivatives. Clin Microbiol Infect 2004: 10 Suppl 1: 86-95.
45. Karthaus M, Cornely OA, Ullmann AJ. Itraconazole versus fluconazole for antifungal prophylaxis. Ann Intern Med 2004; 140: 579-80.
46. Morgenstern GR, Prentice AG, Prentice HG et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999; 105: 901-11.
47. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis. J Clin Oncol 1998; 16: 1179-87.
48. Cruciani M, Rampazzo R, Malena M et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: A meta-analysis. Clin Infect Dis 1996; 23: 795-805.
49. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001; 357: 1766-7.
50. Buggia I, Zecca M, Alessandrino EP et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 1996; 16: 2083-8.
51. Flynn TN, Kelsey SM, Hazel DL et al. Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK. Pharmacoeconomics 1999; 16: 543-50.
52. Wilson LS, Reyes CM, Stolpman M et al. The direct cost and incidence of systemic fungal infections. Value Health 2002; 5 26-34.
53. Uzun O, Anaissie EJ. Antifungal prophylaxis in patients with hematologic malignancies: A reappraisal. Blood 1995; 86: 2063-72.
54. O'Brien SN, Blijlevens NM, Mahfouz TH et al. Infections in patients with hematological cancer: Recent developments. Hematology (Am Soc Hematol Educ Program) 2003; 438-72.
55. Mahfouz T, Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Invest Drugs 2003; 4: 974-90.
56. McLintock LA, Jordanides NE, Allan EK et al. The use of a risk group stratification in the management of invasive fungal infection: A prospective validation. Br J Haematol 2004; 124: 403-4.
57. Reich G, Mapara MY, Reichardt P et al. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant 2001; 27: 525-9.
58. Auner HW, Sill H, Mulabecirovic A et al. Infectious complications after autologous hematopoietic stem cell transplantation: Comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma. Ann Hematol 2002; 81: 374-7.
59. Toor AA, van Burik JA, Weisdorf DJ. Infections during mobilizing chemotherapy and following autologous stem cell transplantation. Bone Marrow Transplant 2001; 28: 1129-34.
60. Ketterer N, Espinouse D, Chomarat M et al. Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: Etiology and potential risk factors. Am J Med 1999; 106: 191-7.
61. Offidani M, Corvatta L, Olivieri A et al. Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. Bone Marrow Transplant 1999; 24: 1079-87.
62. Estey EH, Thall PF, Pierce S et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999; 93: 2478-84.
63. Baddley JW, Stroud TP, Salzman D et al. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319-24.
64. Grow WB, Moreb JS, Roque D et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29: 15-9.
65. Marr KA, Carter RA, Boeckh M et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood 2002; 100: 4358-66.
66. Wald A, Leisenring W, van Burik JA et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-66.
67. Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005; 55 Suppl: (dki220).
68. Odds FC, Van Gerven F, Espinel Ingroff A et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infections models. Antimicrob Agents Chemother 1998; 42: 282-8.
69. Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998; 42: 741-5.
70. Rex JH, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997; 24: 235-47.
71. Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 1998; 35: 461-73.
72. van't Wout JW, van Dissel JT. Fungal infections in hematooncologic patients: Better to prevent than to treat? Blood 2004; 103: 1182.